大学ホーム医学研究科教育・研究指導教員紹介:

教員紹介:久松 理一


氏名
 
久松 理一
ヒサマツ タダカズ HISAMATSU, Tadakazu
職位 教授
学内の役職・委員等 副病院長、消化器内科診療科長、内視鏡室長、炎症性腸疾患包括医療センター長
病院機能評価統括委員会委員長、専門研修プログラム連絡協議会議長、未承認新規医薬品等評価委員会委員長、医学部倫理委員会委員長、医学研究科教務委員会
所属教室
専攻・専門分野
 (大学院)
担当科目(学部) 臨床医学入門, M1プレチュートリアル, M3臨床講義 消化器内科学, CPC, BSL, 臨床総合演習
専門分野 消化器病学、炎症性腸疾患、粘膜免疫学
研究テーマ 炎症性腸疾患の病態解明と新規治療法の確立。腸内細菌と腸管免疫の応答性。メタボローム解析を用いた炎症性腸疾患バイオマーカーの確立。マクロファージ分化における代謝の影響。難治性小腸潰瘍症の病態解明と治療法確立。
略歴 1991年 慶應義塾大学医学部卒
1991年 慶應義塾大学病院内科研修医
1993年 伊勢慶應病院内科
1994年 社会保険埼玉中央病院内科
1995年 慶應義塾大学病院内科専修医(消化器内科)
1997年 東京歯科大学市川総合病院内科 助手
2000年 米国ハーバード大学マサチューセッツ総合病院消化器科研究員
2003年 慶應義塾大学医学部内科学(消化器)助手(現助教)
2008年 慶應義塾大学医学部内科学(消化器)専任講師(学部内)
2010年 慶應義塾大学医学部内科学(消化器)専任講師
2014年 慶應義塾大学医学部内科学(消化器) 准教授
2015年 杏林大学医学部第三内科学(消化器内科)教授
2016年 杏林大学医学部付属病院消化器内科診療科長,内視鏡室長
2019年 杏林大学医学部消化器内科学 教授

現在に至る
所有する学位 博士(医学)
指導医・専門医・認定医、その他の資格等 日本内科学会認定内科医
日本内科学会総合内科専門医
日本内科学会指導医
日本消化器病学会認定専門医
日本消化器病学会指導医
日本消化器内視鏡学会認定専門医
日本消化器内視鏡学会指導医
日本消化管学会胃腸科専門医
日本消化管学会胃腸科指導医
日本医師会認定産業医
日本医師会ACLS研修
教養試験医学系OSCE評価者
GCP(臨床試験の実施基準)概説に関する研修
American College of Gastroenterology, FACG
The American Gastroenterological Association, AGAF
論文・著書等を含む主要研究業績 【主な英文論文(過去5年間)】
Danese S, Panaccione R, Feagan BG, Afzali A, Rubin DT, Sands BE, Reinisch W, Panés J, Sahoo A, Terry NA, Chan D, Han C, Frustaci ME, Yang Z, Sandborn WJ, Hisamatsu T, Andrews JM, D'Haens GR; GALAXI-1 Study Group. Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial
Lancet Gastroenterol Hepatol. 2023 Dec 14:S2468-1253(23)00318-7.
Afif W, Arasaradnam RP, Abreu MT, Danese S, Sandborn WJ, Miao Y, Zhang H, Panaccione R, Hisamatsu T, Scherl EJ, Leong RW, Rowbotham DS, Peyrin-Biroulet L, Sands BE, Marano C. Efficacy and Safety of Ustekinumab for Ulcerative Colitis Through 4 Years: Final Results of the UNIFI Long-term Maintenance Study.
Am J Gastroenterol. 2023 Dec 14.
Peyrin-Biroulet L, Allegretti JR, Rubin DT, Bressler B, Germinaro M, Huang KG, Shipitofsky N, Zhang H, Wilson R, Han C, Feagan BG, Sandborn WJ, Panés J, Hisamatsu T, Lichtenstein GR, Sands BE, Dignass A; QUASAR Study Group. Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study.
Gastroenterology. 2023 Sep 1:S0016-5085(23)04963-6.
Naganuma M, Kobayashi T, Kunisaki R, Matsuoka K, Yamamoto S, Kawamoto A, Saito D, Nanki K, Narimatsu K, Shiga H, Esaki M, Yoshioka S, Kato S, Saruta M, Tanaka S, Yasutomi E, Yokoyama K, Moriya K, Tsuzuki Y, Ooi M, Fujiya M, Nakazawa A, Abe T, Hisamatsu T; Japanese UC Study Group. Real-world efficacy and safety of advanced therapies in hospitalized patients with ulcerative colitis.
J Gastroenterol.2023 Dec;58(12):1198-1210.
Watanabe K, Nojima M, Nakase H, Sato T, Matsuura M, Aoyama N, Kobayashi T, Sakuraba H, Nishishita M, Yokoyama K, Esaki M, Hirai F, Nagahori M, Nanjo S, Omori T, Tanida S, Yokoyama Y, Moriya K, Maemoto A, Handa O, Ohmiya N, Tsuchiya K, Shinzaki S, Kato S, Uraoka T, Tanaka H, Takatsu N, Nishida A, Umeno J, Nakamura M, Mishima Y, Fujiya M, Tsuchida K, Hiraoka S, Okabe M, Toyonaga T, Matsuoka K, Andoh A, Hirota Y, Hisamatsu T; J-COMBAT study group. Trajectory analyses to identify persistently low responders to COVID-19 vaccination in patients with inflammatory bowel disease: a prospective multicentre controlled study, J-COMBAT.
J Gastroenterol.2023 Aug 10.
Matsuoka K, Yamazaki H, Nagahori M, Kobayashi T, Omori T, Mikami Y, Fujii T, Shinzaki S, Saruta M, Matsuura M, Yamamoto T, Motoya S, Hibi T, Watanabe M, Fernandez J, Fukuhara S, Hisamatsu T. Association of ulcerative colitis symptom severity and proctocolectomy with multidimensional patient-reported outcomes: a cross-sectional study.
J Gastroenterol.2023 Aug;58(8):751-765.
Wada H, Miyoshi J, Kuronuma S, Nishinarita Y, Oguri N, Hibi N, Takeuchi O, Akimoto Y, Lee STM, Matsuura M, Kobayashi T, Hibi T, Hisamatsu T. 5-Aminosalicylic acid alters the gut microbiota and altered microbiota transmitted vertically to offspring have protective effects against colitis.
Sci Rep. 2023 Jul 28;13(1):12241.
Ueda T, Koyama F, Sugita A, Ikeuchi H, Futami K, Fukushima K, Nezu R, Iijima H, Mizushima T, Itabashi M, Watanabe K, Hata K, Shinagawa T, Matsuoka K, Takenaka K, Sasaki M, Nagayama M, Yamamoto H, Shinozaki M, Fujiya M, Kato J, Ueno Y, Tanaka S, Okita Y, Hashimoto Y, Kobayashi T, Koganei K, Uchino M, Fujii H, Suzuki Y, Hisamatsu T. Endoscopic lesions of postoperative anastomotic area in patients with Crohn's disease in the biologic era: A Japanese multi-center nationwide cohort study.
J Crohns Colitis. 2023 Jul 14:jjad116.
D'Haens G, Dubinsky M, Kobayashi T, Irving PM, Howaldt S, Pokrotnieks J, Krueger K, Laskowski J, Li X, Lissoos T, Milata J, Morris N, Arora V, Milch C, Sandborn W, Sands BE; LUCENT Study Group (Hisamatsu.T). Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis.
N Engl J Med. 2023 Jun 29;388(26):2444-2455.
Matsuoka K, Fujii T, Okamoto R, Yamada A, Kunisaki R, Matsuura M, Watanabe K, Shiga H, Takatsu N, Bamba S, Mikami Y, Yamamoto T, Shimoyama T, Motoya S, Torisu T, Kobayashi T, Ohmiya N, Saruta M, Matsuda K, Matsumoto T, Nakase H, Maemoto A, Shinzaki S, Murata Y, Yoshigoe S, Sasaki A, Yajima T, Hisamatsu T; iCREST-CD Study Group. Correction: Characteristics of adult patients newly diagnosed with Crohn's disease: interim analysis of the nation-wide inception cohort registry study of patients with Crohn's disease in Japan (iCREST-CD).
J Gastroenterol.2023 Jun;58(6):602-603.
Hirai M, Yanai S, Kunisaki R, Nishio M, Watanabe K, Sato T, Ishihara S, Anzai H, Hisabe T, Yasukawa S, Maeda Y, Takishima K, Ohno A, Shiga H, Uraoka T, Itoi Y, Ogata H, Takabayashi K, Yoshida N, Saito Y, Takamaru H, Kawasaki K, Esaki M, Tsuruoka N, Hisamatsu T, Matsumoto T. The effectiveness of endoscopic resection for colorectal neoplasms in ulcerative colitis: a multicenter registration study.
Gastrointest Endosc. 2023 May 30:S0016-5107(23)02606-8.
Saito D, Hirai F, Uchiyama K, Takagi T, Naito Y, Takatsu N, Tanabe H, Kishimoto M, Matsuura M, Miyoshi J, Watanabe K, Esaki M, Naganuma M, Hisamatsu T. A new endoscopic scoring system corresponding to histological healing using linked color imaging in ulcerative colitis: the SOUL study.
Endosc Int Open. 2023 May 17;11(5):E504-E512.
Nakase H, Esaki M, Hirai F, Kobayashi T, Matsuoka K, Matsuura M, Naganuma M, Saruta M, Tsuchiya K, Uchino M, Watanabe K, Hisamatsu T; TRADE consensus group. Treatment escalation and de-escalation decisions in Crohn's disease: Delphi consensus recommendations from Japan, 2021.
J Gastroenterol. 2023 Apr;58(4):313-345.
Ishige T, Shimizu T, Watanabe K, Arai K, Kamei K, Kudo T, Kunisaki R, Tokuhara D, Naganuma M, Mizuochi T, Murashima A, Inoki Y, Iwata N, Iwama I, Koinuma S, Shimizu H, Jimbo K, Takaki Y, Takahashi S, Cho Y, Nambu R, Nishida D, Hagiwara SI, Hikita N, Fujikawa H, Hosoi K, Hosomi S, Mikami Y, Miyoshi J, Yagi R, Yokoyama Y, Hisamatsu T. Correction to: Expert consensus on vaccination in patients with inflammatory bowel disease in Japan.
J Gastroenterol. 2023 Apr;58(4):431-432.
Yamamoto T, Nakase H, Watanabe K, Shinzaki S, Takatsu N, Fujii T, Okamoto R, Matsuoka K, Yamada A, Kunisaki R, Matsuura M, Shiga H, Bamba S, Mikami Y, Shimoyama T, Motoya S, Torisu T, Kobayashi T, Ohmiya N, Saruta M, Matsuda K, Matsumoto T, Maemoto A, Murata Y, Yoshigoe S, Nagasaka S, Yajima T, Hisamatsu T; iCREST-CD Study Group. Diagnosis and Clinical Features of Perianal Lesions in Newly Diagnosed Crohn's Disease: Subgroup Analysis from Inception Cohort Registry Study of Patients with Crohn's Disease (iCREST-CD).
J Crohns Colitis. 2023 Mar 4:jjad038.
Nakase H, Wagatsuma K, Nojima M, Matsumoto T, Matsuura M, Iijima H, Matsuoka K, Ohmiya N, Ishihara S, Hirai F, Takeuchi K, Tamura S, Kinjo F, Ueno N, Naganuma M, Watanabe K, Moroi R, Nishimata N, Motoya S, Kurahara K, Takahashi S, Maemoto A, Sakuraba H, Saruta M, Tominaga K, Hisabe T, Tanaka H, Terai S, Hiraoka S, Takedomi H, Narimatsu K, Endo K, Nakamura M, Hisamatsu T. Anxiety and behavioral changes in Japanese patients with inflammatory bowel disease due to COVID-19 pandemic: a national survey.
J Gastroenterol. 2023 Mar;58(3):205-216.
Nakase H, Hayashi Y, Yokoyama Y, Matsumoto T, Matsuura M, Iijima H, Matsuoka K, Ohmiya N, Ishihara S, Hirai F, Abukawa D, and Hisamatsu T. Final Analysis of COVID-19 Patients With Inflammatory Bowel Disease in Japan (J-COSMOS): A Multicenter Registry Cohort Study.
Gastreo Hep Advances 2023;2:1056-1065
Ferrante M, Panaccione R, Baert F, Bossuyt P, Colombel JF, Danese S, Dubinsky M, Feagan BG, Hisamatsu T, Lim A, Lindsay JO, Loftus EV Jr, Panés J, Peyrin-Biroulet L, Ran Z, Rubin DT, Sandborn WJ, Schreiber S, Neimark E, Song A, Kligys K, Pang Y, Pivorunas V, Berg S, Duan WR, Huang B, Kalabic J, Liao X, Robinson A, Wallace K, D'Haens G. Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial.
Lancet. 2022 May 28;399(10340):2031-2046. doi: 10.1016/S0140-6736(22)00466-4.
D'Haens G, Panaccione R, Baert F, Bossuyt P, Colombel JF, Danese S, Dubinsky M, Feagan BG, Hisamatsu T, Lim A, Lindsay JO, Loftus EV Jr, Panés J, Peyrin-Biroulet L, Ran Z, Rubin DT, Sandborn WJ, Schreiber S, Neimark E, Song A, Kligys K, Pang Y, Pivorunas V, Berg S, Duan WR, Huang B, Kalabic J, Liao X, Robinson A, Wallace K, Ferrante M. Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials.
Lancet. 2022 May 28;399(10340):2015-2030.
Abreu MT, Rowbotham DS, Danese S, Sandborn WJ, Miao Y, Zhang H, Tikhonov I, Panaccione R, Hisamatsu T, Scherl EJ, Leong RW, Arasaradnam RP, Afif W, Peyrin-Biroulet L, Sands BE, Marano C. Efficacy and Safety of Maintenance Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term Extension.
J Crohns Colitis. 2022 Mar 3:jjac030.
Nakase H, Hayashi Y, Hirayama D, Matsumoto T, Matsuura M, Iijima H, Matsuoka K, Ohmiya N, Ishihara S, Hirai F, Abukawa D, Hisamatsu T; J-COSMOS group. Interim analysis of a multicenter registry study of COVID-19 patients with inflammatory bowel disease in Japan (J-COSMOS).
J Gastroenterol. 2022 Mar;57(3):174-184.
Sandborn WJ, D'Haens GR, Reinisch W, Panés J, Chan D, Gonzalez S, Weisel K, Germinaro M, Frustaci ME, Yang Z, Adedokun OJ, Han C, Panaccione R, Hisamatsu T, Danese S, Rubin DT, Sands BE, Afzali A, Andrews JM, Feagan BG; GALAXI-1 Investigators. Guselkumab for the Treatment of Crohn's Disease: Induction Results From the Phase 2 GALAXI-1 Study.
Gastroenterology. 2022 Feb 5:S0016-5085(22)00102-0.
Miyoshi J, Ozaki R, Yonezawa H, Mori H, Kawamura N, Matsuura M, Hisamatsu T. Ratio of submucosal thickness to total bowel wall thickness as a new sonographic parameter to estimate endoscopic remission of ulcerative colitis.
J Gastroenterol. 2022 Feb;57(2):82-89. doi: 10.1007/s00535-021-01847-3.
Miura M, Shimizu H, Saito D, Miyoshi J, Matsuura M, Kudo T, Hirayama D, Yoshida M, Arai K, Iwama I, Nakase H, Shimizu T, Hisamatsu T. Multicenter, cross-sectional, observational study on Epstein-Barr viral infection status and thiopurine use by age group in patients with inflammatory bowel disease in Japan (EBISU study).
J Gastroenterol. 2021 Dec;56(12):1080-1091.
Miyoshi J, Maeda T, Matsuoka K, Saito D, Miyoshi S, Matsuura M, Okamoto S, Tamura S, Hisamatsu T. Machine learning using clinical data at baseline predicts the efficacy of vedolizumab at week 22 in patients with ulcerative colitis.
Sci Rep. 2021 Aug 12;11(1):16440.
Sakuraba A, Nemoto N, Hibi N, Ozaki R, Tokunaga S, Kikuchi O, Minowa S, Mitsui T, Miura M, Saito D, Hayashida M, Miyoshi J, Matsuura M, Yoneyama M, Ohnishi H, Hisamatsu T. Extent of disease affects the usefulness of fecal biomarkers in ulcerative colitis.
BMC Gastroenterol. 2021 May 1;21(1):197.
Nakase H, Uchino M, Shinzaki S, Matsuura M, Matsuoka K, Kobayashi T, Saruta M, Hirai F, Hata K, Hiraoka S, Esaki M, Sugimoto K, Fuji T, Watanabe K, Nakamura S, Inoue N, Itoh T, Naganuma M, Hisamatsu T, Watanabe M, Miwa H, Enomoto N, Shimosegawa T, Koike K. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020.
J Gastroenterol. 2021 Apr 22.
Kobayashi T, Motoya S, Nakamura S, Yamamoto T, Nagahori M, Tanaka S, Hisamatsu T, Hirai F, Nakase H, Watanabe K, Matsumoto T, Tanaka M, Abe T, Suzuki Y, Watanabe M, Hibi T; HAYABUSA Study Group. Discontinuation of infliximab in patients with ulcerative colitis in remission (HAYABUSA): a multicentre, open-label, randomised controlled trial.
Lancet Gastroenterol Hepatol. 2021 Apr 19:S2468-1253(21)00062-5.
Matsuoka K, Igarashi A, Sato N, Isono Y, Gouda M, Iwasaki K, Shoji A, Hisamatsu T. Trends in corticosteroid prescriptions for ulcerative colitis and factors associated with long-term corticosteroid use: analysis using Japanese claims data from 2006 to 2016.
J Crohns Colitis. 2021 Mar 5;15(3):358-366.
Watanabe K, Tanida S, Inoue N, Kunisaki R, Kobayashi K, Nagahori M, Arai K, Uchino M, Koganei K, Kobayashi T, Takeno M, Ueno F, Matsumoto T, Mizuki N, Suzuki Y, Hisamatsu T. Evidence-based diagnosis and clinical practice guidelines for intestinal Behçet's disease 2020 edited by Intractable Diseases, the Health and Labour Sciences Research Grants.
J Gastroenterol. 2020 May 7.
Hayashida M, Miyoshi J, Mitsui T, Miura M, Saito D, Sakuraba A, Kawashima S, Ikegaya N, Fukuoka K, Karube M, Komagata Y, Kaname S, Okada AA, Fujimori S, Matsuura M, Hisamatsu T. Elevated fecal calprotectin and lactoferrin are associated with small intestinal lesions in patients with Behçet disease.
J Gastroenterol Hepatol. 2020 Jan 30.
Adedokun OJ, Xu Z, Marano C, O'Brien C, Szapary P, Zhang H, Johanns J, Leong RW, Hisamatsu T, van Assche G, Danese S, Abreu MT, Sands BE, Sandborn WJ. Ustekinumab Pharmacokinetics and Exposure Response in a Phase 3 Randomized Trial of Patients With Ulcerative Colitis: Ustekinumab PK and exposure-response in UC.
Clin Gastroenterol Hepatol. 2019 Dec 6.
Sands BE, Sandborn WJ, Panaccione R, O'Brien CD, Zhang H, Johanns J, Adedokun OJ, Li K, Peyrin-Biroulet L, Van Assche G, Danese S, Targan S, Abreu MT, Hisamatsu T, Szapary P, Marano C; UNIFI Study Group. Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis.
N Engl J Med. 2019 Sep 26;381(13):1201-1214.
Hisamatsu T, Kato S, Kunisaki R, Matsuura M, Nagahori M, Motoya S, Esaki M, Fukata N, Inoue S, Sugaya T, Sakuraba H, Hirai F, Watanabe K, Kanai T, Naganuma M, Nakase H, Suzuki Y, Watanabe M, Hibi T, Nojima M, Matsumoto T; DIAMOND2 Study Group. Withdrawal of thiopurines in Crohn's disease treated with scheduled adalimumab maintenance: a prospective randomised clinical trial (DIAMOND2).
J Gastroenterol. 2019 Oct;54(10):860-870.
Hisamatsu T, Matsumoto T, Watanabe K, Nakase H, Motoya S, Yoshimura N, Ishida T, Kato S, Nakagawa T, Esaki M, Nagahori M, Matsui T, Naito Y, Kanai T, Suzuki Y, Nojima M, Watanabe M, Hibi T; DIAMOND study group. Concerns and side effects of azathioprine during adalimumab induction and maintenance therapy for Japanese patients with Crohn's disease: a sub-analysis of a prospective randomized clinical trial (DIAMOND study).
J Crohns Colitis. 2019Sep 19;13(9):1097-1104.
所属学会 日本内科学会(評議員)
日本消化器病学会(関東支部会評議員,関東支部幹事,財団評議員)
日本消化器内視鏡学会(関東支部会評議員,社団評議員)
日本炎症性腸疾患学会(理事,事務局長)
日本消化器免疫学会(理事)
日本臨床免疫学会(理事)
日本消化管学会(理事)
日本大腸肛門病学会(評議員)
日本癌学会
日本臨床腫瘍学会
日本免疫学会
日本ヘリコバクター学会
日本カプセル内視鏡学会(理事)
日本肝臓病学会
日本胆道学会
日本膵臓学会
日本高齢消化器病学会(理事)
日本潰瘍学会
慶應医師会
三鷹医師会
東京都医師会
日本医師会

American College of Gastroenterology (ACG)
The American Gastroenterological Association (AGA)
The American Association of Immunologist (AAI)
Society of Mucosal Immunology (SMI)
Asian Organization for Crohn's & Colitis (AOCC)
European Crohn's and Colitis Organization (ECCO)
公的な委員会等の役員・委員歴 日本学術振興会科学研究費委員会専門委員
(2012-2013,2013-2014,2020-2021,2021- 2022)
日本学術振興会特別研究員等審査会専門委員
(2015-2016,2016.-2017)
日本学術振興会国際事業委員会書面審査委員・書面評価員(2015-2016,2016.-2017)
国立研究開発法人日本医療研究開発機構外部有識者(査読委員)(2016-2017,2017-2018,2018-2019)
厚生労働省保険医療材料専門組織保険医療専門審査員
(2016-2018,2018-2020,2020-2022,2023-2025)
文部科学省大学設置・学校法人審議会大学設置分科会
医専門委員会専門員(2017-2018,2018-2019,2019-2020)
大学改革支援・学位授与機構学位審査委員会専門委員(2018-2023)
厚生労働省科学研究費難治性疾患政策研究事業 難治性炎症性腸管障害に関する調査研究 研究代表者(2020-2022)(2023-2025)
東京都指定難病審査会委員・難病患者認定審査会委員
学外活動2006年- 東京歯科大学市川総合病院消化器科非常勤講師
2015年- 同 客員教授

2015年- 慶應義塾大学医学部内科学(消化器)客員教授
ひとことメッセージ 杏林大学医学部で良医の育成に尽力したいと思います。学生さんや若手医師たちには臆せずどんどん新しいことに挑戦して欲しいです。その機会を提供するのが自分の役割だと考えています。殻は破るためにある!
関連サイト 杏林大学医学部消化器内科学教室
このページのトップへ

PAGE TOP